Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder
by
Popper CW
McLean Hospital,
Belmont, Massachusetts, USA.
CharlesPopperMD@post.harvard.edu
Child Adolesc Psychiatr Clin N Am 2000 Jul; 9(3):605-46, viii

ABSTRACT

Alternatives to psychostimulants are now a routine part of the pharmacologic treatment of ADHD. Bupropion and most tricyclic antidepressants are sound options for managing core behavioral symptoms and, to some extent, cognitive symptoms. Alpha 2 adrenergic agonists can moderately reduce hyperactivity and impulsivity. Certain effective agents, such as desipramine, carbamazepine, neuroleptics, monoamine oxidase inhibitors, are clinically inadvisable in most cases. Lithium, benzodiazepines, antihistaminic sedatives, and buspirone are potentially detrimental. Venlafaxine and beta-adrenergic blockers seem potentially promising. Significant new options include norepinephrine reuptake inhibitors, such as reboxetine and tomoxetine, and possibly selective dopamine agonists. Central anticholinesterases, such as donepezil, may improve core ADHD symptoms and perhaps some associated features that psychostimulants do not--particularly organizational capacity and possibly other executive functions. The potential for bupropion to treat amotivational features should be investigated.

ADHD
Adderall
Overdose
Pregnancy
Precursors
Reboxetine
Stereotypies
Neurotoxicity
CNS stimulants
Self-medication
Dopamine uptake
Canine narcolepsy
AD/HD: new drugs
Genetics and AD/HD
Appetite suppressants
Methamphetamine psychosis
Methamphetamine/narcolepsy
Amphetamine withdrawal/depression
Tomoxetine/atomoxetine (Strattera)
Amphetamine and Ritalin overprescription?

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Cannabis.net
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhappiness?
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World